South-Korea based Hanmi Pharmaceutical is expanding its technology partnership with Medidata, which provides cloud-based solutions for clinical research.
Under the new multi-year enterprise deal, Medidata Clinical Cloud will be incorporated into all clinical trials across Hanmi’s drug development programs.
Hanmi has more than doubled its investment in R&D In the last five years. The company is developing novel therapies to advance care in diabetes, obesity, oncology and auto-immunology.
The pharmaceutical firm has been using Medidata’s unified electronic data capture, management and reporting tool (Medidata Rave) and medical coding capabilities (Medidata Coder) in several of its trials since 2013.
Hanmi will now expand its use of both solutions and use Medidata’s Trial Assurance offering, across its entire clinical development program.
Medidata Trial Assurance assesses the integrity and quality of all clinical and lab data within a clinical trial.
Medidata’s statistical algorithms mine the clinical database automatically and find anomalies, outliers, possible fraud or misconduct and procedural issues.
Hanmi Pharmaceutical vice president Ji-Woong Son said: "Our expanded partnership with Medidata is a key example of the aggressive investments we’re making in R&D to grow our business globally and accelerate drug development, so that we can more quickly and efficiently develop innovative new treatments for patients.
"By leveraging their cloud platform, analytics and deep life sciences industry expertise, we can better ensure productivity and accuracy in our research efforts and the high quality of our clinical data."